Last reviewed · How we verify
high dose ruxolitinib
high dose ruxolitinib is a JAK inhibitor Small molecule drug developed by Beijing Friendship Hospital. It is currently in Phase 3 development for Myelofibrosis, Polycythemia vera.
Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in the signaling of various cytokines involved in inflammation and immune responses.
Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in the signaling of various cytokines involved in inflammation and immune responses. Used for Myelofibrosis, Polycythemia vera.
At a glance
| Generic name | high dose ruxolitinib |
|---|---|
| Sponsor | Beijing Friendship Hospital |
| Drug class | JAK inhibitor |
| Target | JAK1 and JAK2 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting JAK1 and JAK2, ruxolitinib reduces the production of pro-inflammatory cytokines, thereby decreasing inflammation and modulating the immune response. This mechanism is particularly beneficial in treating conditions characterized by excessive or uncontrolled immune activity.
Approved indications
- Myelofibrosis
- Polycythemia vera
Common side effects
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- MAGIC Ruxolitinib for aGVHD (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (PHASE2)
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
- A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis (PHASE1, PHASE2)
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis (PHASE3)
- Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- high dose ruxolitinib CI brief — competitive landscape report
- high dose ruxolitinib updates RSS · CI watch RSS
- Beijing Friendship Hospital portfolio CI
Frequently asked questions about high dose ruxolitinib
What is high dose ruxolitinib?
How does high dose ruxolitinib work?
What is high dose ruxolitinib used for?
Who makes high dose ruxolitinib?
What drug class is high dose ruxolitinib in?
What development phase is high dose ruxolitinib in?
What are the side effects of high dose ruxolitinib?
What does high dose ruxolitinib target?
Related
- Drug class: All JAK inhibitor drugs
- Target: All drugs targeting JAK1 and JAK2
- Manufacturer: Beijing Friendship Hospital — full pipeline
- Therapeutic area: All drugs in Oncology, Immunology
- Indication: Drugs for Myelofibrosis
- Indication: Drugs for Polycythemia vera
- Compare: high dose ruxolitinib vs similar drugs
- Pricing: high dose ruxolitinib cost, discount & access